1Banu, J, Varela, E & Fernandes, G (2012) Alternative therapies for the prevention and treatment of osteoporosis. Nutr Rev 70, 22–40.
2Khosla, S (2010) Update on estrogens and the skeleton. J Clin Endocrinol Metab 95, 3569–3577.
3Al-Anazi, AF, Qureshi, VF, Javaid, K, et al. (2011) Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: an overview. J Nat Sci Biol Med 2, 154–163.
4Gass, M & Dawson-Hughes, B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119, S3–S11.
5Cassidy, A (2003) Dietary phytoestrogens and bone health. J Br Menopause Soc 9, 17–21.
6Zhang, Y, Chen, WF, Lai, WP, et al. (2008) Soy isoflavones and their bone protective effects. Inflammopharmacology 16, 213–215.
7Zhang, Y, Li, Q, Wan, HY, et al. (2009) Genistein and a soy extract differentially affect three-dimensional bone parameters and bone-specific gene expression in ovariectomized mice. J Nutr 139, 2230–2236.
8Lampe, JW (2003) Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 133, Suppl. 3, 956S–964S.
9Mok, SK, Chen, WF, Lai, WP, et al. (2010) Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 159, 939–949.
10Pang, WY, Wang, XL, Mok, SK, et al. (2010) Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. Br J Pharmacol 159, 1693–1703.
11Mei, J, Yeung, SSC & Kung, AWC (2001) High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 86, 5217–5221.
12Zhang, Y, Li, Q, Li, X, et al. (2010) Erythrina variegata extract exerts osteoprotective effects by suppression of the process of bone resorption. Br J Nutr 104, 965–971.
13Chen, WF, Mok, SK, Wang, XL, et al. (2011) Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. Br J Nutr 105, 180–189.
14Zhang, Y, Li, Q, Wan, HY, et al. (2011) Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo. Osteoporos Int 22, 703–709.
15Zhou, Q (2003) Clinical application of Drynaria in orthopedics and traumatology. J Tradit Chin Orthop Traumatol 15, 59.
16Sun, JS, Dong, GC, Lin, CY, et al. (2003) The effect of Gu-Sui-Bu (Drynaria fortunei J. Sm) immobilized modified calcium hydrogenphosphate on bone cell activities. Biomaterials 24, 873–882.
17Jeong, JC, Lee, JW, Yoon, CH, et al. (2004) Drynariae rhizoma promotes osteoblast differentiation and mineralization in MC3T3-E1 cells through regulation of bone morphogenetic protein-2, alkaline phosphatase, type I collagen and collagenase-1. Toxicol In Vitro 18, 829–834.
18Jeong, JC, Lee, JW, Yoon, CH, et al. (2005) Stimulative effects of Drynariae rhizoma extracts on the proliferation and differentiation of osteoblastic MC3T3-E1 cells. J Ethnopharmacol 96, 489–495.
19Jeong, JCLB, Yoon, CH, Kim, HM, et al. (2005) Effects of Drynariae rhizoma on the proliferation of human bone cells and the immunomodulatory activity. Pharm Res 51, 125–136.
20Wong, RW & Rabie, AB (2006) Systemic effect of crude extract from rhizome of Drynaria fortunei on bone formation in mice. Phytother Res 20, 313–315.
21Wong, RW, Rabie, B, Bendeus, M, et al. (2007) The effects of rhizoma Curculiginis and rhizoma Drynariae extracts on bones. Chin Med 2, 13.
22Sun, JHW & Liu, K (2008) The research of Drynaria total flavonoids and osteoporosis research. Chin J Osteo 14, 763–766.
23Chen, LLLL, Ding, PH, Tang, Q, et al. (2011) Osteogenic effect of Drynariae rhizome extracts and naringin on MC3T3-E1 cells and an induced rat alveolar bone resorption model. Arch Oral Biol 56, 1655–1662.
24Guo, D, Wang, J, Wang, X, et al. (2011) Double directional adjusting estrogenic effect of naringin from rhizoma Drynariae (Gusuibu). J Ethnopharmacol 138, 451–457.
25Jeong, JC, Kang, SK, Youn, CH, et al. (2003) Inhibition of Drynariae rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. Int Immunopharmacol 3, 1685–1697.
26Wang, XL, Wang, NL, Zhang, Y, et al. (2008) Effects of eleven flavonoids from the osteoprotective fraction of Drynaria fortunei (KUNZE) J. SM. on osteoblastic proliferation using an osteoblast-like cell line. Chem Pharm Bull (Tokyo) 56, 46–51.
28Wang, XL, Wang, NL, Gao, H, et al. (2010) Phenylpropanoid and flavonoids from osteoprotective fraction of Drynaria fortunei. Nat Prod Res 24, 1206–1213.
29Wang, X, Zhen, L, Zhang, G, et al. (2011) Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of Drynaria fortunei – an in vitro efficacy study. Phytomedicine 18, 868–872.
30Wang, XLWN, Wong, MS & Yao, XS (2008) Phenylpropanoid compounds isolated from Drynaria fortunei and their proliferation effects on UMR 106 cells. J Shenyang Pharm Univ 25, 24–29.
31Lu, Y, Zhang, C, Bucheli, P, et al. (2006) Citrus flavonoids in fruit and traditional Chinese medicinal food ingredients in China. Plant Foods Hum Nutr 61, 57–65.
32Wei, M, Yang, Z, Li, P, et al. (2007) Anti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis model. Am J Chin Med 35, 663–667.
33Mandadi, K, Ramirez, M, Jayaprakasha, GK, et al. (2009) Citrus bioactive compounds improve bone quality and plasma antioxidant activity in orchidectomized rats. Phytomedicine 16, 513–520.
34Wu, JB, Fong, YC, Tsai, HY, et al. (2008) Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Eur J Pharmacol 588, 333–341.
35Li, L, Zeng, Z & Cai, G (2011) Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine 18, 985–989.
36Xie, F, Wu, CF, Lai, WP, et al. (2005) The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med 2, 353–361.
37Wong, RW & Rabie, AB (2006) Effect of naringin on bone cells. J Orthop Res 24, 2045–2050.
38Chang, EJ, Lee, WJ, Cho, SH, et al. (2003) Proliferative effects of flavan-3-ols and propelargonidins from rhizomes of Drynaria fortunei on MCF-7 and osteoblastic cells. Arch Pharm Res 26, 620–630.
39Kosuge, K, Mitsunaga, K, Koike, K, et al. (1994) Studies on the constituents of Ailanthus integrifolia. Chem Pharm Bull (Tokyo) 42, 1669–1671.
40Gasser, JA & Willnecker, J (2012) Bone measurements by peripheral quantitative computed tomography in rodents. Methods Mol Biol 816, 477–498.
41Zhang, Y, Leung, PC, Che, CT, et al. (2008) Improvement of bone properties and enhancement of mineralization by ethanol extract of Fructus Ligustri Lucidi. Br J Nutr 99, 494–502.
42Lau, WS, Chan, RY, Guo, DA, et al. (2008) Ginsenoside Rg1 exerts estrogen-like activities via ligand-independent activation of ERalpha pathway. J Steroid Biochem Mol Biol 108, 64–71.
43Xie, Y-M, Xu, Y-G, Zhao, J-N, et al. (2004) Effect of osteopractic total flavone on density of bones of rats without ovaria and levels. China J Basic Med Tradit Chin Med 10, 34–37.
44Zhang, J, Li, HP, Yang, PL, et al. (2009) Effects of total flavonoids from rhizoma Drynariae medicated serum on proliferation, differentiation, cell cycle and apoptosis of osteoblasts in vitro. Zhong Yao Cai 32, 1090–1093.
45Pang, WYWX, Mok, SK, Lai, WP, et al. (2010) Naringin activates estrogen receptor ligand-independently in rat osteoblast-like (UMR 106) cells and improves bone properties in ovariectomized mice. Br J Pharmacol 159, 1693–1703.
46Bord, S, Ireland, DC, Beavan, SR, et al. (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32, 136–141.
47Chen, XW, Garner, SC & Anderson, JJ (2002) Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem Biophys Res Commun 295, 417–422.
48Zhu, H, Wang, WJ & Wang, ZM (2010) Effects of Drynariae rhizoma total flavone on Smad1 Smad5 mRNA expression in osteoporosis. Chin Arch Trad Chin Med 28, 200–204.